TITLE

Breathing Easier

AUTHOR(S)
Egan, Mary
PUB. DATE
September 2006
SOURCE
Forbes Asia;9/18/2006, Vol. 2 Issue 15, p110
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information on the drugs developed by Inspire Pharmaceuticals and Vertex Pharmaceuticals for the treatment of cystic fibrosis. Cystic fibrosis drowns the lungs in abnormally thick, sticky mucus and devastates the pancreas, liver and other organs. Inspire developed a synthetic version of uridine triphosphate, called denufosol, which can be inhaled by patients through a nebulizer. Vertex's compound, VX-770, restores function not only to the lungs but also to other organs affected by cystic fibroris.
ACCESSION #
22512890

 

Related Articles

  • More Positive Data for CF Drug; Vertex Eyes 2H11 NDA.  // Bioworld Week;4/4/2011, Vol. 19 Issue 14, p3 

    The article reports on a positive data for cystic fibrosis (CF) drug VX-770 in adult patients as well as the revelation of a study by Vertex Pharmaceuticals Inc. which involves 6 to 11 aged children that shows a good trend towards support on the proposed new drug application (NDA).

  • Vertex CF Results Positive, But No Home Run.  // Bioworld Week;6/13/2011, Vol. 19 Issue 24, p5 

    The article reports that the phase two trial conducted by Vertex Pharmaceuticals Inc. involving the combination of two drugs for cystic fibrosis (CF) had shown positive interim results but these are not viewed as home run.

  • Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis.  // Biomedical Market Newsletter;5/14/2011, p806 

    The article presents information on the collaboration between Vertex Pharmaceuticals Inc., and Cystic Fibrosis Foundation Therapeutics Inc., regarding the continued discovery and development of correctors. Correctors refer to medicines, which aim to treat the underlying cause of cystic fibrosis....

  • CF Patient Power Fuels Early Kalydeco Approval. Serebrov, Mari // BioWorld Insight;2/13/2012, Vol. 20 Issue 7, p3 

    The article presents information on early approval of a new drug named as Kalydeco developed by the cystic fibrosis team of Vertex Pharmaceuticals Inc. It is stated that the company harnessed the power and experience of various cystic fibrosis patients for the development of this drug which is...

  • Vertex Receives European CHMP Positive Opinion for KALYDECO(tm) (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article informs that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion by consensus recommending the approval of KALYDECO (ivacaftor) from Vertex Pharmaceuticals Inc. KALYDECO has been developed to treat people with cystic fibrosis (CF) ages 6...

  • Excitement mounts for first disease-modifying cystic fibrosis drugs. Opar, Alisa // Nature Reviews Drug Discovery;Jul2011, Vol. 10 Issue 7, p479 

    The article focuses on advancements on various drugs for treating cystic fibrosis which are ready for regulatory submission. It mentions the VX-770 from Vertex Pharmaceuticals Inc. which was shown to have the ability to open up the cystic fibrosis transmembrane conductance regulator (CFTR) to...

  • New drug hits root of cystic fibrosis. Coghlan, Andy // New Scientist;3/5/2011, Vol. 209 Issue 2802, p18 

    The article looks at VX-770, an experimental drug developed by Vertex Pharmaceuticals which treats defects in a protein which causes cystic fibrosis. The drug works by correcting problems with the cystic fibrosis transmembrane regulator (CFTR), which forms channels for the movement of chloride...

  • Vertex's Cystic Fibrosis Drug Shows Promise in Patent Trial. Chambers, Heather // San Diego Business Journal;4/7/2008, Vol. 29 Issue 14, p12 

    The article reports on the development of an investigational drug by Vertex Pharmaceuticals Inc. for patients with cystic fibrosis on March 27, 2008. The company stated that its oral drug candidate, which targets a basic defect in cystic fibrosis, showed a promising result in an ongoing Phase 2a...

  • First 'breakthrough' drugs designated, but dilution worries linger. Dolgin, Elie // Nature Medicine;Feb2013, Vol. 19 Issue 2, p116 

    The article focuses on the benefits of and concerns over the U.S. Food and Drug Administration (FDA)'s new rule which speeds up market authorization of new drugs by designating them breakthrough therapy. It mentions that Vertex Pharmaceuticals Inc. has received the FDA approval for its cystic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics